Revision as of 12:01, 27 January 2023

Section editor
	Seema Nagpal, MD Stanford University Palo Alto, CA

This page has regimens that are not specific to any one type of cancer. For disease-specific regimens, please go to the following pages:

1 regimens on this page 1 variants on this page

Guidelines

2022: Schiff et al. Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline

2021: Le Rhun et al. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
2017: Le Rhun et al. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours

WBRT: Whole-Brain Radiation Therapy

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Knisely et al. 2007 (RTOG 0118)	2002-2004	Phase 3 (C)	Thalidomide & WBRT	Did not meet primary endpoint of OS

One course

RTOG 0118: Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):79-86. Epub 2007 Dec 31. link to original article contains dosing details in abstract PubMed NCT00033254

@@ Line 23: / Line 23: @@
 ==[http://www.asco.org/ ASCO]==
 *'''2022:''' Schiff et al. [https://doi.org/10.1200/jco.22.00333 Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline]
-*'''2022:''' Ramakrishna et al. [https://doi.org/10.1200/JCO.22.00520 Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases]
-===Older===
-*'''2018:''' Ramakrishna et al. [https://doi.org/10.1200/JCO.2018.79.2713 Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline update] [https://pubmed.ncbi.nlm.nih.gov/29939840 PubMed]
-*'''2014:''' Ramakrishna et al. [https://doi.org/10.1200/JCO.2013.54.0955 Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline] [https://pubmed.ncbi.nlm.nih.gov/24799487 PubMed]
 ==ASCO/SNO/ASTRO==
 *'''2021:''' Vogelbaum et al. [https://doi.org/10.1200/JCO.21.02314 Treatment for Brain Metastases]
@@ Line 34: / Line 30: @@
 ==[https://www.nccn.org/ NCCN]==
 *[https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf NCCN Guidelines - Central Nervous System Cancers]
 =All lines of therapy=
 ==Whole brain irradiation {{#subobject:6115dc|Regimen=1}}==